Department of Medicine, University Hospitals and Case Western Reserve University, Cleveland, Ohio.
Section of Hematology/Oncology, Department of Medicine, Northwestern University, Chicago, Illinois.
Cancer. 2021 Jun 1;127(11):1827-1835. doi: 10.1002/cncr.33324. Epub 2021 Feb 1.
The use of herbs and supplements (HS) is common among patients with cancer, yet limited information exists about potential medication interactions (PMIs) with HS use around chemotherapy.
Patients with breast or prostate cancer who had recently finished chemotherapy at 2 academic medical centers were surveyed by telephone. Interviewers inquired about all medications, including HS, before, during, and after chemotherapy. Micromedex, Lexicomp, and Natural Medicines Comprehensive Database interaction software programs were used to determine PMIs.
A total of 67 subjects (age range, 39-77 years) were evaluated in this study. Participants were primarily White patients (73%) with breast cancer (87%). The median number of medications was 11 (range, 2-28) during the entire study and was highest during chemotherapy (7; range, 2-22). Approximately four-fifths (84%) used HS. A total of 1747 PMIs were identified, and they represented 635 unique PMIs across all 3 timeframes, with most occurring during chemotherapy. Prescription-related PMIs (70%) were the most common type, and they were followed by HS-related (56%) and anticancer treatment-related PMIs (22%). Approximately half of the PMIs (54%) were categorized as moderate interactions, and more than one-third (38%) were categorized as major interactions. Patient use of HS increased from 51% during chemotherapy to 66% after chemotherapy, and this correlated with an increased prevalence of HS PMIs (46% to 60%). HS users were more likely to be at risk for a major PMI than non-HS users (92% vs 70%; P = .038).
The use of HS remains prevalent among patients with cancer and may place them at risk for PMIs both during chemotherapy and after the completion of treatment.
This study evaluates the risk of potential medication interactions for patients with breast or prostate cancer undergoing chemotherapy. The results show that patients often use herbs and supplements during treatment. Prescription medications are most often associated with medication interactions, which are followed by herb and supplement-related interactions. More than one-third of potential medication interactions are considered major. Patients should be educated about the risk of herb and supplement-related medication interactions during treatment.
癌症患者普遍使用草药和补充剂（HS），但关于化疗期间使用 HS 与潜在药物相互作用（PMIs）的信息有限。
在 2 家学术医疗中心接受化疗的乳腺癌或前列腺癌患者通过电话接受调查。访谈者询问了化疗前、化疗期间和化疗后的所有药物，包括 HS。使用 Micromedex、Lexicomp 和 Natural Medicines Comprehensive Database 交互软件程序来确定 PMIs。
本研究共评估了 67 名患者（年龄 39-77 岁）。参与者主要为白人患者（73%），患有乳腺癌（87%）。整个研究期间，参与者使用的药物中位数为 11 种（范围 2-28 种），化疗期间最高（7 种；范围 2-22 种）。大约五分之四（84%）的患者使用 HS。共发现 1747 个 PMIs，涉及所有 3 个时间框架的 635 个独特 PMIs，大多数发生在化疗期间。与处方相关的 PMIs（70%）是最常见的类型，其次是 HS 相关的 PMIs（56%）和抗癌治疗相关的 PMIs（22%）。大约一半的 PMIs（54%）被归类为中度相互作用，超过三分之一（38%）被归类为严重相互作用。化疗期间 HS 使用者从 51%增加到化疗后 66%，这与 HS PMIs 的发生率增加（46%至 60%）相关。HS 使用者比非 HS 使用者更有可能面临严重 PMIs 的风险（92%比 70%；P =.038）。
癌症患者中 HS 的使用仍然普遍，这可能使他们在化疗期间和治疗结束后面临潜在药物相互作用的风险。
本研究评估了接受化疗的乳腺癌或前列腺癌患者发生潜在药物相互作用的风险。结果表明，患者在治疗期间经常使用草药和补充剂。与药物相互作用最相关的是处方药物，其次是草药和补充剂相关的相互作用。超过三分之一的潜在药物相互作用被认为是严重的。应在治疗期间向患者进行有关草药和补充剂相关药物相互作用风险的教育。
